Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Is Bristol-Myers Squibb Company BMY the Best Weight Loss Stock to Buy Now According to Hedge Funds?

December 25, 2024
Bristol-Myers Squibb Company (BMY) is gaining attention from investors as it emerges as a potential weight loss stock to buy. Hedge funds have been increasing their positions in the company, indicating confidence in its growth prospects. This comes as no surprise, considering BMY's strong pipeline of obesity treatments, which are showing promising results in clinical trials. With the increasing prevalence of obesity worldwide, the demand for effective weight loss medications is on the rise. Investors looking to capitalize on this trend may want to consider adding BMY to their portfolio. For a more accurate forecast of the company's stock movement, it is recommended to consult professionals at Stocks Prognosis.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved  ~1 min.

On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....


BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit  ~1 min.

QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....


BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....


BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....


BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....


GSKNovember 17, 2024GSK's Ojjaara Receives Health Canada Approval for Myelofibrosis in Anemia Patients  ~1 min.

GSK PLC, a leading pharmaceutical company, has received approval from Health Canada for its groundbreaking drug, Ojjaara, to be used in the treatment of myelofibrosis in anemia patients....


PFEFebruary 28, 2025Pfizer Inc. PFE Announces Groundbreaking Cancer Treatment: Here is What You Should Know  ~2 min.

Pfizer Inc. PFE has recently made a groundbreaking announcement in the field of cancer treatment, attracting significant attention from investors....


VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....


ABBVDecember 13, 2024AbbVie Inc. Makes Groundbreaking Acquisition to Expand Alzheimer's Pipeline  ~2 min.

AbbVie Inc., a leading pharmaceutical company, has recently made a significant acquisition to expand its pipeline in the field of Alzheimer's disease....


VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....